Tirzepatide on TikTok: What the caption gets right and wrong

What did @m_fa_comercializadora actually say?

Honestly, it's hard to tell. The video's caption does most of the heavy lifting here, claiming tirzepatide is FDA-approved, works weekly, and delivers a "double action" via GIP and GLP-1 receptors for weight and blood sugar control. The spoken transcript, however, is a word-salad of disconnected phrases about "putting words on lips" and finding "a great place for our fellow professional." There are no direct medical claims in the audio. What we can evaluate is the caption, because that's what 23,000 viewers actually read.

The caption calls tirzepatide a "ally against obesity and diabetes" and promotes something called the "GLP-1 PEN." That framing, combined with "pide info" (ask for info), suggests this is promotional content for a product or service, not educational content. That distinction matters for how we read every claim attached to it.

Does the science back this up?

The core science referenced in the caption is real and reasonably well-supported. Tirzepatide does act on both GIP and GLP-1 receptors. That dual mechanism is not marketing copy. It's the actual pharmacology. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed participants with obesity lost up to 20.9% of body weight over 72 weeks, which is a clinically meaningful result.

For type 2 diabetes, the SURPASS trial program (Ludvik et al., 2021, The Lancet) confirmed significant HbA1c reductions compared to both placebo and active comparators. The FDA approved tirzepatide as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023. So the "FDA-approved" claim and the "double action" mechanism claim are both accurate, in the context of those brand-name drugs. What the caption does not say, and what matters enormously, is whether this "GLP-1 PEN" is brand-name or compounded tirzepatide. That gap is not a small detail.

What did they get wrong (or right)?

Let's give credit where it's due: the mechanism description is correct. Tirzepatide is a dual GIP and GLP-1 receptor agonist. That's not spin, that's the pharmacology (Frias et al., 2021, NEJM). Weekly dosing is also accurate for the approved products.

Here's where it gets problematic. The phrase "FDA approved" applied to a vaguely named "GLP-1 PEN" is misleading if this product is compounded tirzepatide. Compounded tirzepatide is not FDA-approved. The FDA has issued statements clarifying that compounded versions of tirzepatide are not the same as Mounjaro or Zepbound, and that the approval does not extend to compounded formulations. Calling a compounded product FDA-approved because the active ingredient has FDA approval elsewhere is like saying a store-brand acetaminophen tablet is "FDA-approved" because Tylenol is. It's technically adjacent to the truth but functionally misleading to a consumer.

The framing of tirzepatide as an "ally against obesity and diabetes" stops short of saying it cures either condition, so it avoids the most egregious compliance violations. But the overall tone of the video, promotional, vague about product identity, and inviting direct inquiries, raises real questions about regulatory compliance for drug marketing.

What should you actually know?

If you're considering tirzepatide, the clinical evidence is genuinely strong. The SURMOUNT and SURPASS trial programs are among the most robust weight and diabetes datasets we've seen in years. But the route to getting it matters as much as the drug itself.

• Brand-name Mounjaro and Zepbound are FDA-approved and manufactured under controlled conditions. Compounded tirzepatide is not FDA-approved, and quality, sterility, and dosing accuracy vary by compounder.
• The FDA has repeatedly warned that compounded drugs carry risks that approved drugs don't, including contamination and inaccurate dosing.
• Tirzepatide is a prescription medication. Any platform or individual selling or promoting it without a licensed prescriber involved in the clinical decision is operating outside standard of care.
• Common side effects include nausea, vomiting, diarrhea, and constipation, especially during dose escalation. These are not trivial for many patients.
• "Pide info" from a social media account is not a substitute for a licensed clinician evaluating your individual health history, contraindications, and medications.

The science behind tirzepatide is real. The way this video packages and sells access to it deserves more scrutiny than the caption suggests.